Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

Five years ago, volunteers rolled up their sleeves in the first clinical trial of a vaccine against COVID-19, as the new ...

Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...

Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors ...

Click here and access our complete analysis report ... investor Starboard, Pfizer has remained resilient. Its strategic alliances in the oncology space and continued investment in pipeline ...

Relay Therapeutics, Inc.’s RLAY share price has dipped by 6.00%, which has investors questioning if this is right time to buy.

Pfizer intends to sell its remaining residual ... [email protected] We sell different types of products and services to both investment professionals and individual investors.

The money spent to develop, test, buy and administer the first COVID-19 vaccine was more than made up for by prevented medical care and lost productivity.

Market OverviewThe global Vaccines Market has evolved significantly in recent years, driven by advancements in biotechnology, ...